The past decade has seen tremendous changes in China's economic, political and regulatory aspects, and have led to an unprecedented consolidation in the industry. These changes have fostered competitiveness among the remaining Chinese manufacturers who increasingly recognise the need to upgrade to enter into the regulated markets and also to have some balance of sales on the domestic market. This paper will examine how seven companies are dealing with the current challenges and what strategies they are implementing to become contenders in the international arena. All have tremendous potential but have inherent problems that must be overcome to emerge as pharmaceutical ‘powers’.
ChandlerC. (2004). Inside the new China. Fortune Magazine, 4th October, p. 86.
2.
LiF. (2006). Mergers and acquistions. China Pharmaceut. Rev.3, June 15. p. 20.
3.
Simcere Pharmaceutical Group (2006). Lenovo's Hony Capital joined hands with Simcere Pharmaceutical Group to pave way into pharmaceutical industry. Simcere Pharmaceutical Group, http://www.simcere.com/english/news/detail.asp?id=18, accessed 10th September, 2006.
Author's interview with JunDuMr, CEO and Mr Hai Wang, Vice President, Business Development, Huahai US Inc., New York, 20th June, 2006.
9.
Author's interviews with QunbinWangMr, President, Mr Phillip Cui, Vice President, Mr Jin Zhongren, Director of International Development Fosun Pharmaceutical Group Co. Ltd, Shanghai, 6th June and 18th September, 2006.
